

Cumulated Subject Index

Vol.1, No.1-6; Vol.2, No.1-5, 1971

A

Abactrim
see trimethoprim-sulphamethoxazole

Abortion

post-conception pill 1: 482

septic

coagulation, disseminated intravascular 1:
233-234

spontaneous

contraceptives, hormonal 2: 156

compared with

intrauterine contraceptive device 2: 156

therapeutic

blood loss during: effect of anaesthesia and
pulmonary ventilation on 1: 90

Abruptio placentae

coagulation, disseminated intravascular 1: 233-234,
312

Accidents, automobile

compared with

contraceptives, hormonal mortality risk 2: 25
mortality rate 2: 28

Acetclidine

glaucoma, open angle

compared with pilocarpine 1: 493

Acetaminophen

see paracetamol

Acetazolamide

diuretic effect 1: 68

drug poisoning: in management of 1: 156

hyperuricaemia 1: 160

mode of diuretic action 1: 68

ocular reactions 1: opp 172

structural formula 1: 65

Acetohexamide

insulin, plasma: effect on 1: 127

Acetylcholine

excitatory-inhibitory imbalance in Parkinsonism 2:
327, 329

excitatory transmitter in striatum 2: 330

Parkinsonism: role in 1: 87

Acetylsalicylic acid

see aspirin

Achlorhydria

influence on aspirin-induced occult gastro-intestinal
blood loss in Addisonian pernicious anaemia 2: 472

Achromycin

see tetracyclines

Acid-base balance

carbonic anhydrase in renal regulation 1: 62, 64

diuretics and 1: 61

mafenide 1: 456, 458

renal regulation 1: 62-65

Acid, titratable

of urine 1: 63

Acidification

urine: renal clearance trimethoprim 1: 41

Acidifiers, urinary

trimethoprim-sulphamethoxazole: antibacterial
synergy 1: 47

Acidosis, hypochloraemic

mafenide 1: 445, 449

Acidosis, metabolic

carbonic anhydrase inhibitors 1: 69

mafenide 1: 456, 458

p-sulphamoylbenzoic acid 1: 456

tris hydroxymethyl aminomethane 1: 497-498

Acidosis, respiratory

tris hydroxymethyl aminomethane 1: 497-498

Acne

contraceptives, oral 1: 247

trimethoprim-sulphonamides in 1: 31

Acne vulgaris

levodopa 2: 314

Acromegaly

causes of death 1: 256

medroxyprogesterone: in management of 1: 255

morbidity in 1: 256

mortality in 1: 255-256

treatment of 1: 255, 256

ACTH

ocular reactions 1: opp 172

Actin

digitalis action 1: 84

Actinomycin D

enzyme induction 2: 180

- Adeno viruses
rifampicin *I*: 382
- Adenoidectomy
otitis media, acute *2*: 456-457
- Adenosine diphosphate (ADP)
blood coagulation mechanism *I*: 229
platelet aggregation-induced RA433: inhibition by *I*: 237
platelets: release of *I*: 229
- Adenosine monophosphate, cyclic (AMP)
diazoxide effect on *2*: 107-108, 211
glibenclamide *I*: 129
metabolism: interference by aminophylline *I*: 78
- Adenosine triphosphatase
digitalis action *I*: 84, 85
digitalis sensitive sodium-potassium activated and proximal tubular function *I*: 57
digoxin assays *I*: 85
ethacrynic acid: inhibition of *I*: 71
frusemide: inhibition of *I*: 73
- Adenyl cyclase
glibenclamide *I*: 129
- Adrenal
contraceptives, hormonal *I*: 416-417
- Adrenaline
asthma *I*: 279
bronchodilator activity *I*: 285
cardiovascular effects *I*: 285
catecholamine biosynthesis *2*: 333
levodopa metabolism *2*: 355
ocular reactions *I*: opp 172
structural formula *I*: 271
structure-activity relationships *I*: 269
- Adrenaline eye drops
hypersensitivity *2*: 8, 11
medrysone *2*: 8
tetrahydrotriamcinolone *2*: 11
- Adrenergic neurone blocking agents
interaction with
antidepressants, tricyclic *I*: 222, 224
- Adrenergic receptors
bronchodilators and asthma *I*: 269
classification *I*: 270
- β -Adrenergic receptors
bronchodilators: effect on *I*: 290-291
classification *I*: 290
drug action *I*: 290
isoprenaline: effect on *I*: 290
oriprenaline: effect on *I*: 290
pharmacological stimuli *I*: 270, 290
salbutamol: effect on *I*: 270, 290-291
- β -Adrenergic receptor blocking agents
interaction with sulphonylureas *I*: 136
methylphenidate cardiovascular toxicity: effect on *I*: 489
ocular reactions *I*: opp 172
oxprenolol *I*: 489
+ a piperidino-pyrimidine derivative
hypertension in management of *I*: 249-250
in poisoning mixed antidepressant drugs *I*: 89
- β -Adrenergic receptors, bronchial
see β_2 -adrenergic receptors
- β -Adrenergic receptors, cardiac
see β_1 -adrenergic receptors
- β_1 -Adrenergic receptors
cardiac stimulation and *I*: 290
isoprenaline: effect on *I*: 290
pharmacological stimuli *I*: 270
see also β -adrenergic receptors
- β_2 -Adrenergic receptor blocking agents
practolol *I*: 290
- β_2 -Adrenergic receptors
bronchodilation and *I*: 290
isoprenaline: effect on *I*: 290
oriprenaline: selectivity for *I*: 290
pharmacological stimuli *I*: 270
salbutamol: selectivity for *I*: 270, 290-291
see also β -adrenergic receptors
- Adrenocortical functional
corticosteroids, intermittent regimen *2*: 235
corticosteroids, long-term *2*: 235
- Adrenocortical insufficiency
contraceptives, hormonal *I*: 417
- Aflatoxin toxicity
barbiturate protection *2*: 184
- Agkistrodon rhodostoma
Malayan pit viper
see ancond
- Agranulocytosis
anticoagulants: indanediones *I*: 315
ethacrynic acid *I*: 492
mafenide *I*: 456
p-sulphamoylbenzoic acid *I*: 456
trimethoprim-sulphamethoxazole *I*: 45
- Agranulocytosis, drug-induced
prevention of infection in by trimethoprim-sulphamethoxazole *I*: 45
- AH 3365
see salbutamol
- Alastrim virus
rifampicin *I*: 382
- Albumin binding
diazoxide *2*: 75, 125-126
- Alcohol
driving skills
marihuana *I*: 168
enzyme induction *2*: 181-182
interaction with
glibenclamide *I*: 137
marihuana *I*: 167-168
sulphonylureas *I*: 136-137
- Alcoholics, chronic
drug metabolism, inhibition *2*: 229-230
enzyme induction *2*: 182
- Alcoholics, depressed chronic
diazepam treatment *I*: 199
doxepin treatment *I*: 199
- Alcoholism
rifampicin
jaundice *I*: 395
jaundice, lack of *I*: 390
rifampicin + isoniazid
jaundice *I*: 389-391
- Aldactone
see spironolactone

- Aldactone—A**
see spironolactone
- Aldosterone**
contraceptives, oral and hypertension *I*: 96
diuretics: inhibition of *I*: 62
hypertension
 contraceptives, oral *I*: 142–143
ion exchange control of in distal nephron *I*: 62, 63
sodium reabsorption: control of in distal nephron *I*: 59, 62
- Aldosterone antagonists *I*: 74–75**
in cardiac failure *I*: 75
diuretics, combined with *I*: 75, 144
heart failure: right sided *I*: 144–145
hyperaldosteronism and oedematous states *I*: 75
hyperkalaemia *I*: 75
hypokalaemia, diuretic-induced:
 prevention of *I*: 75
in liver cirrhosis *I*: 75
mode of action *I*: 74
in nephrotic syndrome *I*: 75
renal failure and hyperkalaemia *I*: 75
site of action in nephron *I*: 75
sodium reabsorption: inhibition of in nephron *I*: 74
spironolactone *I*: 74, 144
- Aldosteronism, primary**
associated with hypertension
 detected with diazoxide *I*: 120
spironolactone *I*: 155
triarterene *I*: 155
- Aldosteronism, secondary**
spironolactone *I*: 155
triarterene *I*: 155
- Alkaline phosphatase**
levodopa interference *I*: 377–379
- Alkalinisation**
urine: renal clearance sulphamethoxazole *I*: 41
- Alkalinisers, urinary**
trimethoprim-sulphamethoxazole: antibacterial synergy *I*: 47
- Alkalosis**
hypochloreaemic hypokalaemic
 ethacrynic acid *I*: 72
 frusemide *I*: 74
hypokalaemic, diuretic-induced: prevention by
 aldosterone antagonists *I*: 75
 triarterene *I*: 76
- Alkalosis, metabolic**
potassium depletion causes *I*: 62
sodium delivery and distal nephron *I*: 61
- Alkalosis, respiratory**
mefenide *I*: 458
- Allergy**
anaesthesia *I*: 48–49
anaesthetics, local *I*: 48
coagulation, disseminated intravascular *I*: 233–234
non-volatile drugs *I*: 48
otorhinolaryngological procedures *I*: 48–49
surgery *I*: 48–49
- Allopurinol**
drug metabolism, impairment *I*: 231
in gout *I*: 412
- hyperuricaemia: prevention of during thiazide therapy *I*: 160
thrombocytopenia: in conjunction with
 trimethoprim-sulphamethoxazole *I*: 50
- Alopecia**
anticoagulants
 coumarins *I*: 315
 heparin *I*: 314
 indanediones *I*: 315
contraceptives, oral *I*: 247; *I*: 150–151
- Amantadine**
adverse reactions *I*: 89; *I*: 317
catecholamine release *I*: 336
compared with
 levodopa
 Parkinsonism *I*: 315–317
dopamine release enhancement *I*: 336
dosage *I*: 315–317
+ levodopa
 Parkinsonism *I*: 314–317
 mode of action *I*: 336
levodopa potentiator *I*: 314–317
livedo reticularis *I*: 317
Parkinsonism placebo-controlled trial *I*: 88
 idiopathic *I*: 88
 postencephalitic *I*: 88
 thalamolysis, previous *I*: 88
- Amantadine-levodopa combination**
see levodopa-amantadine combination
- Ambamide**
see mafenide
- Amblyopia, toxic**
drug-induced *I*: opp 172
ibuprofen *I*: 443–444
- Amenorrhoea**
contraceptives, hormonal *I*: 413–414, 474, 476
medroxyprogesterone acetate *I*: 477
progestagens, injectable *I*: 477
suggestion: effect of on *I*: 468–469
- American Diabetes Association**
recommendations of use
 hypoglycaemic agents, oral *I*: 113
- American Medical Association**
recommendations of use
 hypoglycaemic agents, oral *I*: 113
- Amiloride *I*: 65, 76, 77**
distal tubule: action on *I*: 76
glomerular filtration rate *I*: 76
mode of action *I*: 76
potassium excretion: prevention of *I*: 76
renal failure *I*: 76
sodium reabsorption nephron: site of inhibition *I*: 77
structural formula *I*: 65
use with
 ethacrynic acid *I*: 76
 thiazides *I*: 76
- Aminocaproic acid**
see epsilon aminocaproic acid
- p-Aminohippurate**
diazoxide: effect on clearance *I*: 119
- γ-Aminolevulinic synthetase**
enzyme induction *I*: 226

- p*-(Aminomethyl) benzenesulfonamide
see mafenide
- Aminomethylcyclohexane carboxylic acid
adverse reactions *I*: 316
dosage *I*: 242
fibrinolysis: inhibition of *I*: 242
fibrinolytic enzyme system: site of action *I*: 232
mode of action *I*: 242
- Aminophylline
adenosine monophosphate, cyclic, metabolism: interference by *I*: 78
adverse reactions *I*: 162
glomerular filtration rate *I*: 77
heart failure: left-sided *I*: 145-146
mode of diuretic action *I*: 77, 78
nephrotic syndrome *I*: 149-150
oedema, cardiac *I*: 145-146
oedema, cirrhotic *I*: 148
renal blood flow *I*: 77
- Aminoquinolines
ocular reactions *I*: 339
- Aminorex fumarate
adverse reactions *I*: 468
pulmonary hypertension: drug-induced *I*: 468
- α -Aminotoluene-*p*-sulphonamide
see mafenide
- Amitriptyline
adverse reactions *I*: 213, 215, 217
anxiety/depression, mixed
compared with
doxepin *I*: 210, 212
anticholinergic effects *I*: 215, 217
depression
compared with
doxepin *I*: 191, 199, 210, 212-217
dosage
anxiety/depression, mixed *I*: 210, 212
depression *I*: 213-216
liver function studies *I*: 215
ocular reactions *I*: opp 172
pharmacology
compared with
doxepin *I*: 191, 217-222
schizophrenia *I*: 217
structural formula *I*: 223
- Amitriptyline + perphenazine
adverse reactions *I*: 211, 212, 216
anxiety/depression, mixed
compared with
doxepin *I*: 209, 210, 211
depression
compared with doxepin *I*: 191, 215
dosage
anxiety/depression, mixed *I*: 209, 210, 211
depression *I*: 214-216
gastro-intestinal effects *I*: 216
- Ammonium chloride
drug poisoning: in management of *I*: 156
- Ammonium ions
acid-base balance: renal regulation *I*: 63, 64
- Amniotic fluid embolism
coagulation, disseminated intravascular *I*: 233-234, 312
- AMP, cyclic
see adenosine monophosphate, cyclic
- Amphetamines
action: noradrenaline hypothesis *I*: 190
drug poisoning: treatment of *I*: 156
ocular reactions *I*: opp 172
- Amphotericin B
leukaemia, acute: dental care *I*: 97
- Ampicillin
antibacterial activity compared with
trimethoprim-sulphamethoxazole *I*: 37
compared with
trimethoprim-sulphamethoxazole
in chronic urinary infections *I*: 21
in exacerbations of chronic bronchitis *I*: 13, 16
gonorrhoea *I*: 320-323, 325
otitis media, acute *I*: 456-457
synergy with trimethoprim *I*: 36
- Amyloidosis, systemic
coagulation, disseminated intravascular *I*: 233-234
- Anacyclin
composition *I*: 472
- Anaemia
Addisonian pernicious
influence of achlorhydria on aspirin-induced occult
gastro-intestinal blood loss *I*: 472
contraceptives, hormonal *I*: 41-42
deficiency
folate *I*: 203, 220
iron *I*: 196-197, 214-215
vitamin B₁₂ *I*: 217-219
haemolytic
levodopa *I*: 375
+ Ro4-4602 *I*: 321, 375
megaloblastic *I*: 198, 203-205, 220
pernicious *I*: 200-201
refractory *I*: 213
- Anaesthesia
allergy *I*: 48-49
blood loss during therapeutic abortion: effect of on *I*: 90
- Anaesthesia, general
levodopa *I*: 385-386, 387
- Anaesthesia, thiopentone
sulphafurazole enhancement *I*: 454
- Anaesthetic agents
causing sensitisation *I*: 48
enzyme induction *I*: 181
ocular reactions *I*: opp 172
- Anaesthetics, local
allergy *I*: 48
benzocaine lozenges in dental care acute leukaemia *I*: 97
- Analgesics
arthritis *I*: 411-413
in dental practice *I*: 471-472
enzyme induction *I*: 181
ibuprofen *I*: 420-421, 436
morphine-like
ocular reactions *I*: opp 172
pentazocine
compared with
pethidine in labour *I*: 488

- Analgesics, local
see anaesthetics, local
- Anastomoses, intraperitoneal
chemoprophylaxis *I*: 251
- Anastomotic breakdown
bowel surgery: prevention of *I*: 251-252
neostigmine and *I*: 169
- Ancrod
anticoagulant activity *I*: 307; 2: 167
blood coagulation mechanism: site of action *I*: 230
dosage *I*: 235-236
fibrinogen: effect on *I*: 235
hypersensitivity reactions *I*: 235
indications for use *I*: 307
mode of action *I*: 235
resistance, acquired *I*: 235
reversal of action *I*: 236
thrombo-embolism 2: 167
toxicity: animals *I*: 235
- Androgenic, anabolic steroids
interaction with coumarin anticoagulants *I*: 313
- Angina pectoris
anticoagulant therapy *I*: 305
- Angiomas, spider
contraceptives, oral *I*: 247; 2: 151
- Angio-oedema
contraceptives, oral 2: 151
- Angiotensin
hypertension - contraceptives, oral *I*: 142-143
- Angiotensinogen
hypertension
contraceptives, oral *I*: 142
- Anisindione
dosage *I*: 236
duration of effect *I*: 236
- Anisocytosis
iron deficiency anaemia 2: 197
- Ankylosing spondylitis
ibuprofen 2: 434-435
- Anovlar
composition *I*: 472
- Anovlar 21
composition *I*: 472
- Antacid
levodopa absorption increased 2: 352
- Anthranilates
see flufenamic acid
mefenamic acid
- Antianxiety agents
chlordiazepoxide *I*: 191, 200-202, 204-205,
207-209
diazepam *I*: 191-192, 199-207
doxepin *I*: 190-192, 199-213
drug trials *I*: 191-192, 196
meprobamate *I*: 190
placebo *I*: 190
- Antiarrhythmic drugs
bretylum tosylate 2: 74, 465-467
digitalis *I*: 85
lignocaine 2: 242
phenytoin 2: 243
procainamide 2: 242
quinidine 2: 242
- Antibacterial agents
rifampicin *I*: 381
trimethoprim *I*: 3, 7
trimethoprim-sulphamethoxazole *I*: 3, 7-53
typhoid fever; failure to perform in accordance with
theoretical expectation *I*: 4
- Antibacterial agents, topical
burn wound sepsis *I*: 432-433, 434-460
comparison of *I*: 440-442
- Antibiotics
bowel surgery, large: chemoprophylaxis in *I*: 254
burn wound sepsis *I*: 430-431
eye infections 2: 1
ocular reactions *I*: opp 172
- Antibiotics affecting the intestinal flora
interaction with coumarin anticoagulants *I*: 313
- Anticholinergic drugs
duodenal ulcer *I*: 95
glycopyrronium 2: 50
- Parkinsonism
+ levodopa 2: 317-318, 344, 383
mode of action *I*: 87
poldine 2: 50
intraocular pressure and systemic administration 2:
237
ocular reactions: *I*: opp 172
open-angle glaucoma 2: 236-237
withdrawal causing hypersalivation 2: 318
- Anticholinergics, long-term
gastric acid secretion: effect on 2: 50-51
parietal cell mass: effect on 2: 50-51
- Anticoagulants *I*: 234-237
adverse reactions *I*: 314-315
ancrod *I*: 235-236, 307; 2: 167
antagonists *I*: 241
atherosclerosis, ischaemic attacks *I*: 304
blood coagulation mechanism: effect on *I*: 230
cardiac valves, prosthetic: following insertion of *I*:
304
cerebral ischaemic attack, transient *I*: 306
choice of *I*: 306
contra-indications *I*: 316-317
coronary artery disease *I*: 305-306
coronary insufficiency, acute *I*: 305-306
coumarin *I*: 236-237, 313-316
enzyme induction 2: 182
dosage *I*: 235-236
drug interactions *I*: 313-314
with chloral hydrate 2: 54
nicoumalone and rifampicin *I*: 392
duration of effect *I*: 236
ethyl biscoumacetate *I*: 306
factors interfering with therapy *I*: 312-314
fetal haemorrhage *I*: 308
fibrin reduction *I*: 304
heart disease, rheumatic with embolism *I*: 304
heart failure, congestive: increased sensitivity in *I*: 313
heparin *I*: 234-235, 304, 306-309, 311, 314
heparin prophylaxis in postoperative thrombo-
embolism 2: 239
host determinants of response *I*: 313
indanediones *I*: 236-237, 315, 316
indications for use *I*: 304-306

- laboratory control *I*: 243-244
 prothrombin time *I*: 243
 thrombotest *I*: 243
 liver disease: increased sensitivity in *I*: 313
 myocardial infarction *I*: 305-306
 pharmacology *I*: 234-237
 phenindione *I*: 304, 306
 placental transfer *I*: 308
 pregnancy *I*: 308
 puerperium *I*: 308
 pulmonary embolism *I*: 304-306
 selection of oral preparations *I*: 306
 site of action *I*: 230
 surgery *I*: 307-308
 thrombo-embolism *I*: 305
 thrombosis, deep vein *I*: 304, 305-306
 thrombosis, disseminated intravascular *I*: 306
 warfarin sodium *I*: 306, 330
- Anticoagulant antagonists *I*: 241**
 protamine sulphate *I*: 242
 vitamin K₁ *I*: 241
- Anticonvulsants**
 dysmorphic effect *I*: 92-93
 epilepsy *I*: 243-244
 enzyme induction *I*: 181-182
 folate deficiency *I*: 92-93
 folate deficiency and trimethoprim-sulphamethoxazole *I*: 48
 ocular reactions *I*: opp 172
 phenytoin intoxication *I*: 45-46
 sulthiame *I*: 471
- Antidepressants**
 anti-anxiety agents and *I*: 191
 classification of *I*: 191
 drug trials *I*: 190-192
 ocular reactions *I*: opp 172
 phenothiazines *I*: 191
 poisoning: multiple *I*: 89
- Antidepressants, monoamine oxidase inhibitors**
 action of: noradrenaline hypothesis *I*: 190
- Antidepressants, tricyclic**
 action of: noradrenaline hypothesis *I*: 190
 amitriptyline *I*: 191, 199, 210, 212-217
 amitriptyline + perphenazine *I*: 209-211, 213-215
 doxepin *I*: 191-192, 194-227
 elderly: use in the *I*: 197, 222, 226
 imipramine *I*: 190, 199, 217
 interaction with
 adrenergic neurone blocking agents *I*: 224
 reserpine *I*: 224
 thyroid drugs *I*: 224-225
 + levodopa *I*: 321, 370, 383-384
 nortriptyline *I*: 51
 ocular reactions *I*: opp 172
 pharmacological action *I*: 191
 prescribing habits *I*: 459
 + thyroid hormone in depression *I*: 165, 166
- Antidiuretic hormone**
 urinary concentration: role in *I*: 58, 59
- Antifibrinolytic drugs**
 adverse reactions *I*: 316
 aminomethylcyclohexane carboxylic acid *I*: 242, 316
 aprotinin *I*: 242
 epsilon aminocaproic acid *I*: 241-242, 316
 fibrinolytic enzyme system: site of action *I*: 232
- Antifungal agents**
 leukaemia, acute: dental care
 amphotericin B *I*: 97
 nystatin *I*: 97
- Antihistamines**
 enzyme induction *I*: 281
 eye infections *I*: 1
 ocular reactions *I*: opp 172
- Antihypertensive agents**
 β -adrenergic blocking agents *I*: 249-250
 bethanidine *I*: 56
 clonidine *I*: 248-249
 diazoxide *I*: 156, 248; *I*: 83-102
 mode of action *I*: 107-108
 site of action *I*: 106-107
 guanethidine and contraceptives, oral *I*: 96
 + levodopa *I*: 382
 α -methyldopa *I*: 56
 ocular reactions *I*: opp 172
 a piperidino-pyrimidine derivative *I*: 249-250
 reserpine *I*: 56
 spirinolactone *I*: 155
 stroke survivors *I*: 173-174
 thiazides *I*: 154-156
 triamterene *I*: 155
- Anti-inflammatory agents**
 betamethasone *I*: 11
 colchicine *I*: 54-55
 corticosteroid, topical *qv*
 dexamethasone *I*: 9, 11-12
 hydrocortisone *I*: 7
 ibuprofen *I*: 420, 435
 medrysone *I*: 5-19
 prednisolone *I*: 12
 prostaglandins *I*: 412
 rheumatic disorders *I*: 411-415
 tetrahydrotriamicinolone *I*: 11
 therapeutic assessment *I*: 414
 see also antirheumatic agents
- Anti-inflammatory steroids**
 intraocular pressure: medrysone *I*: 1-4, 10-12
- Antileukaemic drugs**
 L-asparaginase *I*: 487
 cytarabine *I*: 485-486
- Antimalarial drugs**
 aminoquinolines *I*: 339
 chloroquine *I*: 339
 hydroxychloroquine *I*: 339
 ocular reactions *I*: 172; opp 172
 rheumatoid arthritis *I*: 339
 mode of action *I*: 339
- Antimicrobial agents**
 ocular reactions *I*: opp 172
 rifampicin *I*: 374-384
 trimethoprim *I*: 3, 7
 trimethoprim-sulphamethoxazole *I*: 3, 7-53
- Antimicrobial activity**
 against *Enterobacter aerogenes* *I*: 458
 against *Enterobacter cloacae* *I*: 458
- Antimony compounds**
 ocular reactions *I*: opp 172

- Antimycobacterial agents
rifampicin *I*: 375-381
- Antineoplastic agents
asparaginase: clinical evaluation *I*: 487
bleomycin: clinical evaluation *I*: 487
cytarabine: kinetics of tumour cell kill in leukaemia *I*: 485-486
- Antiparkinsonian agents
amantadine *I*: 88; 2: 315-317
levodopa *I*: 87; 2: 257-261, 271-307
ocular reactions *I*: opp 172
- Antiplasmins
 α_1 -antitrypsin *I*: 231
fibrinolytic enzyme system: inhibitor of *I*: 231-232
 α_1 -macroglobulin *I*: 231
- Antiplatelet agents *I*: 237-238
dipyridamole *I*: 237, 307
pharmacology *I*: 237-238
RA 233 *I*: 238
RA 433 *I*: 237
- Antipyretic therapy
evaluation of oral therapy 2: 238
evaluation of sponging 2: 238
ibuprofen 2: 436
paracetamol 2: 238
- Antipyretics
ocular reactions *I*: opp 172
- Antipyrine
see phenazone
- Antirheumatic agents
adverse reactions 2: 413
allopurinol 2: 412
aspirin 2: 411-412, 420-425, 427-429
chloroquine 2: 412
corticosteroids 2: 411-412
corticotrophin 2: 411-412
flufenamic acid 2: 420, 426-427
gold salts 2: 412
hydroxychloroquine 2: 412
ibuprofen 2: 411-446
ideal 2: 414-415
indomethacin 2: 411-413, 421, 431-432
mefenamic acid 2: 412
ocular reactions *I*: opp 172
oxyphenbutazone 2: 411-412
paracetamol 2: 411, 421, 426, 430
penicillamine 2: 412
phenylbutazone 2: 411-413, 420, 422-423
probenecid 2: 412
propoxyphene 2: 411
psychotropic drugs 2: 412
therapeutic trials 2: 413-415
- Antiseptics, topical
burn wound sepsis *I*: 431-433
burns: control of bacterial population *I*: 431-433
- Antispasmodics
ocular reactions *I*: opp 172
- Antithrombotic drugs
dipyridamole *I*: 307
- Antithyroid drugs
ocular reactions *I*: opp 172
- α_1 -Antitrypsin
contraceptives, oral 2: 148
fibrinolytic enzyme system: inhibitor of *I*: 231
- Antituberculosis agents
capreomycin *qv*
cycloserine *qv*
elderly *I*: 350
ethambutol *qv*
ethionamide *qv*
isoniazid *qv*
ocular reactions *I*: opp 172
pyrazinamide *qv*
rifampicin *qv*
thiacetazone *qv*
thioarlide *qv*
viomycin *qv*
- Antiviral agents
rifampicin *I*: 381-382, 383
- Anxiety, acute
levodopa 2: 371
- Anxiety
see anxiety neurosis
- Anxiety/depression, mixed
doxepin *I*: 191, 209-213
compared with
amitriptyline *I*: 210, 212
amitriptyline + perphenazine *I*: 209-212
placebo *I*: 209
dosage *I*: 198, 209-212
- Anxiety neurosis
doxepin *I*: 190-192, 199-213
compared with
chlordiazepoxide *I*: 191, 200-202, 204-205, 207-209
diazepam *I*: 191-192, 199-207
placebo *I*: 199, 203
dosage *I*: 200, 203-209
drug trials *I*: 191-192
psychotropic drugs and *I*: 189-192
treatment *I*: 189-190
- Aphthous stomatitis
tetracycline 2: 240
therapeutic management 2: 240-241
- Apnoea
newborn: tris hydroxymethyl aminomethane-induced *I*: 497-498
- Apoferitin
iron storage 2: 195
- Apomorphine
Parkinsonism 2: 330
- Aponal
see doxepin
- Apoprotein synthesis
oestrogen 2: 147
- Aprotinin
dosage *I*: 242
fibrinolytic enzyme system *I*: 232, 242
kallikrein: inhibition of *I*: 242
mode of action *I*: 242
- Aromatic L-amino acid decarboxylase
catecholamine biosynthesis 2: 333
dopamine biosynthesis 2: 258
levodopa metabolism 2: 355

- Arrhythmias, cardiac
levodopa 2: 260
- Arrhythmias, ventricular
phenytoin 2: 243
- Arrhythmias, ventricular, adrenaline-induced
methoxyflurane effects on 2: 463-464
- Arsenicals
ocular reactions 1: opp 172
- Arteriography
diazoxide 2: 100-101
- Arteriolar dilation
diazoxide 2: 74
- Artery, coeliac
contraceptives, hormonal 2: 35
- Artery, mesenteric
contraceptives, hormonal 2: 36
- Arthritis, gonococcal
antibiotic treatment regimen 1: 321
- Arthritis, psoriatic
ibuprofen 2: 434-435
- Arthritis, rheumatoid
analgesics 2: 411-413
anti-inflammatory agents 2: 411-415
antimalarial drugs 1: 339
antirheumatic agents 2: 412-415
aspirin 1: 329; 2: 245, 411-412
compared with ibuprofen 2: 420-430
corticosteroids 1: 495-496; 2: 411-412
indications for 1: 496
corticotrophins 2: 411-412
flufenamic acid
compared with
ibuprofen 2: 420, 426-427
ibuprofen 2: 419-430
compared with
aspirin 2: 420-430
flufenamic acid 2: 420, 426-427
paracetamol 2: 421, 426, 430
phenylbutazone 2: 420, 422-423
placebo 2: 419-420, 423-430
prednisolone 2: 420, 423-425, 428-429
long-term maintenance therapy 2: 432-435
indomethacin 1: 329; 2: 411-413
indomethacin, evening doses 2: 245
iron preparations, parenteral 2: 216
oxyphenbutazone 2: 411-412
paracetamol 2: 411
compared with
ibuprofen 2: 421, 426, 430
phenylbutazone 2: 411-413
compared with
ibuprofen 2: 420, 422-423
prednisolone
compared with
ibuprofen 2: 420, 423-425, 428-429
propoxyphene 2: 411
salicylates 2: 245
treatment 2: 411-412
- Arvin
see anrod
- Ascites
management in patients with liver cirrhosis 2: 241
treatment of 1: 147-149
- Ascorbic acid
iron absorption 2: 193, 210
- L-Asparaginase
clinical evaluation 1: 487
leukaemia 1: 487
lymphoblastic leukaemia 1: 487
myeloblastic leukaemia 1: 487
toxicity 1: 487
- Aspergillus oryzae*
protease 1: 240
- Aspergillus proteases*
proteolytic enzymes 1: 238
- Aspirin
adverse reactions 2: 422-423, 426, 428-430
brain recovery after overdosage 1: 252
dosage
rheumatoid arthritis 2: 420-425, 427-429
dysmorphogenic effect 1: 91
gastro-intestinal effect
blood loss 2: 437-438
interactions with
indomethacin 1: 329
otitis media, acute 2: 455
rheumatoid arthritis 2: 245, 411-412
compared with ibuprofen 2: 420-430
- Artherosclerosis
ischaemic attacks
anticoagulant therapy 1: 304
- Asthma
adrenaline 1: 279, 285
adrenergic receptors and bronchodilators 1: 269
exercise-induced
disodium cromoglycate 1: 296
salbutamol 1: 295
hypothalamo-pituitary adrenal function using long-term corticosteroids 2: 234-235
isoprenaline 1: 270, 277, 281, 283-285, 287-288
isoprenaline + atropine methonitrate 1: 278-279, 285
oriprenaline 1: 277-279, 282, 285, 287
salbutamol 1: 270, 276-289
- Asthma, cardiac
diuretics in 1: 146
- Atrial fibrillation
digoxin plasma concentrations 2: 57-58
hyperthyroidism and digoxin dosage 1: 82
quinidine in maintenance of sinus rhythm after electrical conversion of 1: 337
- Atrophy, genital
contraceptives, hormonal: choice of 1: 478
- Atropine
bowel activity: effect on in anaesthetised subjects 1: 168-169
- Atropine sulphate
open-angle glaucoma 2: 237
parietal cell structure: effect on 2: 50
- Auralgan
see benzocaine-phenazone
- Autonomic nervous system
chemical transmitters 1: 269
- Azathioprine
serum immunosuppressive activity and its relation to hepatic function after liver transplantation 2: 467-468

Azotaemia

- diazoxide 2: 85, 91, 98-100
- methoxyflurane 2: 53
- ototoxicity and ethacrynic acid 1: 492
- tetracyclines and 1: 332
- see also nephritis, chronic

B**B80**

- see ibuprofen

Ba 41, 166

- see rifampicin

Bacitracin

- bowel surgery, large: chemoprophylaxis in 1: 251-252

Bacitracin, neomycin, polymixin B

- pyoderma in children 2: 59

Bacterial infections, miscellaneous

- rifampicin 1: 372-374

Bacteriuria

- of pregnancy and trimethoprim-sulphamethoxazole 1: 22

Bactrim

- see trimethoprim-sulphamethoxazole

Barbiturates

- aflatoxin toxicity, protection by 2: 184
- drug poisoning: treatment of 1: 156
- enzyme induction 2: 181, 233
- folate deficiency and trimethoprim-sulphamethoxazole 1: 48
- interaction with
 - coumarin anticoagulants 1: 313
 - marihuana 1: 168
 - rifampicin 1: 393
- + levodopa 2: 384
- ocular reactions 1: opp 172
- renal failure: drug intoxication
 - neurological episodes 1: 169

Baroreceptors

- diazoxide 2: 96

Basal ganglia

- Parkinsonism 2: 324

Bendopa

- see levodopa

Bendrofluazide

- dosage, diuretic 1: 143
- structural formula 1: 69

Bendroflumethiazide

- see bendrofluazide

Benzhexol

- + levodopa
 - Parkinsonism 2: 297

Benzocaine

- lozenges: dental care in acute leukaemia 1: 97

Benzocaine-phenazone

- otitis media, acute 2: 455

Benzodiazepine derivatives

- interaction with rifampicin 1: 393

Benzothiadiazines

- hypertension 2: 102-103
- + levodopa 2: 383
- see also thiazides

3,4-Benzpyrene hydroxylase

- carcinogen susceptibility of cigarette smoke 2: 184

Benzylpenicillin

- antibacterial activity compared with trimethoprim-sulphamethoxazole 1: 37
- burn wound sepsis prophylaxis 1: 440
- gonorrhoea 1: 320-325

Benzylpenicillin, oral

- otitis media, acute 2: 455-457

Benzylpenicillin sodium

- see benzylpenicillin

Betamethasone

- intraocular pressure elevation
 - compared with medrysone 2: 11

Bethanidine

- hypertension, essential
 - compared with α -methyl dopa and reserpine 2: 56
- interaction with
 - desipramine 1: 222
 - doxepin 1: 222, 224

Biguanides

- fibrinolytic activity 1: 240-241
- glibenclamide, addition of 1: 122-123, 124

Bile

- rifampicin 1: 386

Biliary disease

- contraceptives, hormonal 2: 159

Biliary obstruction

- anticoagulant requirements 1: 313, 316

Bilirubin

- enzyme induction 2: 183
- phenobarbitone induction of 2: 183

Bilirubin glucuronyl transferase

- phenobarbitone 2: 183

Bilirubin, serum

- levodopa interference 2: 378-379
- phenobarbitone effect on 2: 183

Bioavailability

- general considerations 2: 448
- phenytoin capsules and excipient change 2: 45-46

Biodopa

- see levodopa

Biogenic amines

- depression and noradrenaline hypothesis 1: 190
- see also dopamine
 - noradrenaline
 - serotonin

Biopharmaceutics

- bioavailability 2: 449-451

Bishydroxycoumarin

- see dicoumarol

Blastomycosis

- trimethoprim-sulfadoxine 1: 31

Bleomycin

- adverse reactions 1: 488
- cancer therapy 1: 487-488
- clinical evaluation 1: 487-488
- epithelial tumours 1: 488
- haemopoiesis: effect on 1: 488
- mode of action 1: 487
- toxicity 1: 488

Blepharitis

- management 2: 1

Blood-brain barrier

- diazoxide 2: 134

- Blood clot
 - formation *I*: 231
- Blood clotting
 - contraceptives, hormonal effect on *I*: 29, 39-40
- Blood clotting factors
 - blood coagulation mechanism *I*: 230-231, 233, 236
 - fibrinolytic enzyme system *I*: 231
- Blood coagulation mechanism *I*: 229-231
 - anticoagulants
 - site of action *I*: 230
 - chlormadinone acetate, effect on *I*: 40
 - contraceptives, hormonal *I*: 38-40
 - disorders of
 - coagulation, disseminated intravascular *I*: 233-234
 - hyperplasmaemic states *I*: 233
 - ethinylloestradiol and mestranol: relative potency *I*: 405
 - extrinsic pathway *I*: 230-231
 - intrinsic pathway *I*: 230
- Blood dyscrasias
 - trimethoprim-sulphamethoxazole *I*: 45-47
- Blood flow, coronary
 - diazoxide *I*: 105-106, 118
- Blood flow, peripheral
 - diazoxide *I*: 118
- Blood flow, regional
 - diazoxide *I*: 105
- Blood gas tensions
 - bronchodilators: assessment of changes *I*: 295-296
 - isoprenaline *I*: 297
 - practolol *I*: 290
 - salbutamol *I*: 295-297
- Blood gas values
 - mafenide *I*: 458
- Blood groups
 - contraceptives, hormonal and thrombo-embolism association *I*: 40-41
- Blood loss
 - abortion, therapeutic, during: effects of anaesthesia and pulmonary ventilation on *I*: 90
 - aspirin *I*: 437-438
 - ibuprofen *I*: 437-438
 - lactose *I*: 437-438
 - paracetamol *I*: 437-438
 - phenylbutazone *I*: 437-438
- Blood pressure
 - contraceptives, oral and measurement of *I*: 96
 - diazoxide *I*: 115-116
 - animals *I*: 103-104
 - compared with
 - other antihypertensive agents *I*: 116
 - mode of action *I*: 74-75
 - dopamine *I*: 340-341
 - levodopa *I*: 340-341, 345-346, 373-374
 - see also hypertension
- Blood pressure, high
 - see hypertension
- Blood sugar
 - diazoxide *I*: 87, 89, 94, 96, 121-122
 - animals *I*: 110
 - compared with
 - other antihypertensive agents *I*: 122
 - levodopa *I*: 350, 378-380, 384
- Blood transfusion
 - iron deficiency anaemia: condemnation *I*: 215
 - vitamin B₁₂ deficiency anaemia: condemnation *I*: 219
- Blood urea nitrogen
 - diazoxide *I*: 84-85, 89, 91, 96
 - diazoxide + frusemide *I*: 98-100
 - levodopa interference *I*: 377-380
- Blood vessels, nasal
 - histamine, effect on *I*: 46
 - isoprenaline, effect on *I*: 46
 - prostaglandin, effect on *I*: 46
 - serotonin, effect on *I*: 46
- Bone disease, metabolic
 - biochemical advances *I*: 469
 - clinical advances *I*: 469
 - management *I*: 469-470
- Bone marrow iron stores
 - iron deficiency anaemia *I*: 197
- Bowel activity
 - neostigmine: anaesthetised subjects *I*: 168
- Bowel, surgery: large
 - chemoprophylaxis *I*: 251, 253-254
 - anastomotic breakdown: prevention of *I*: 251
 - effect of incidence of local recurrence *I*: 254
 - penicillin, intravenous: effect on incidence post-operative infection *I*: 253
 - penicillin-resistant organisms *I*: 253-254
 - dextran, low molecular weight *I*: 251-252
- Bowman's capsule
 - fluid from *I*: 55
- Bradykinesia
 - levodopa *I*: 303-304
 - see also hypokinesia
- Brain
 - abnormalities in Parkinsonism *I*: 325, 328
 - dopamine concentration *I*: 328
 - noradrenaline concentration *I*: 328
- Brain recovery, late
 - drug overdose *I*: 250
- Breakthrough bleeding
 - contraceptives, hormonal *I*: 475
 - 17- α -hydroxyprogesterones *I*: 475
 - 19-nortestosterones *I*: 475
 - oestrogens *I*: 475
 - sequential regimen, reverse *I*: 480
 - suggestion: effect on *I*: 468-469
- Breast cancer
 - ethynone *I*: 154
 - oestradiol *I*: 155
 - oestriol *I*: 155
 - oestrone *I*: 155
 - see also breast lesions
- Breast fibroadenomas
 - contraceptives, hormonal *I*: 154
- Breast lesions
 - contraceptives, hormonal
 - sequential regimen *I*: 154-156
- Breast-milk
 - anticoagulants, oral *I*: 308
 - contraceptives, hormonal *I*: 412
 - levodopa *I*: 387
- Breast tissue lesions
 - neoplasia - contraceptives, hormonal *I*: 154-156

Breasts

- contraceptives, hormonal *I*: 411-412
- lack of development
 - contraceptives, hormonal: choice of *I*: 478

Bretylium tosylate

- hypertensive crises 2: 74
- myocardial infarction, acute 2: 465-466

Brocadopa

- see levodopa

Bromsulphthalein, serum

- levodopa interference 2: 378-379

Bromsulphthalein test

- mestranol 2: 148-149
- norethynodrel 2: 148-149

Bronchial infection

- Pseudomonas*: treatment *I*: 335

Bronchitis, acute

- trimethoprim-sulphamethoxazole *I*: 16

Bronchitis, chronic

- exacerbations of, prevention
 - trimethoprim-sulphamethoxazole in *I*: 5, 14, 17-18
- exacerbations of, treatment in
 - trimethoprim-sulphamethoxazole in *I*: 5, 12-17

- isoprenaline *I*: 279, 285, 287
- orciprenaline *I*: 279, 285, 287
- salbutamol *I*: 279, 285, 287

Bronchodilators

- adrenaline *I*: 269, 279, 285
- adrenergic receptors and asthma *I*: 269
- blood gas tensions: assessment of changes *I*: 295-296
- isoprenaline *I*: 270, 277-296
- orciprenaline *I*: 277-298
- salbutamol *I*: 270-273, 274-302
- terbutaline *I*: 301

Bronchopneumonia

- mafénide *I*: 453

Bronchospasm

- see bronchodilators

Brucellosis, acute

- trimethoprim-sulphamethoxazole *I*: 30

Brufen

- see ibuprofen

Buccal mucosa

- contraceptives, oral 2: 151-152

BUN

- see blood urea nitrogen

Burn mortality in children

- mafénide era
 - compared with
 - pre-mafénide era *I*: 438
- Burn wound sepsis**
- antibacterial agents compared *I*: 440-442
 - mortality rate *I*: 441
 - antibiotics prophylactically *I*: 440
 - antibiotics, systemic: use in *I*: 431
 - antiseptic control *I*: 431-433, 440-442
 - benzylpenicillin prophylactically *I*: 440
 - cross infection *I*: 430
 - furazolidine *I*: 446-447
 - gentamicin *I*: 431, 440-442

 β -haemolytic streptococcus *I*: 429-433

- mafénide *I*: 432, 434-449, 451-452, 458
- compared with
 - furazolidine *I*: 446-447
 - gentamicin *I*: 440-441
 - neomycin-chlorhexidine-polymyxin cream *I*: 445
 - polymyxin-bacitracin *I*: 447
 - silver nitrate *I*: 440-442, 447-449
 - silver sulphadiazine *I*: 440-442
- pneumonia: death from *I*: 445-446
- management of *I*: 429-433
- neomycin-chlorhexidine-polymyxin cream *I*: 445
- pathogenic bacteria in the environment reduction *I*: 430
- penicillin *I*: 429, 431
- polymyxin-bacitracin *I*: 447
- Pseudomonas* spp. *I*: 429-433
- silver nitrate *I*: 440-442, 447-449
- silver sulphadiazine *I*: 433, 440-442
- sulphonamides *I*: 429, 432
- verdoglobinuria
 - gentamicin *I*: 440

Burns, severe

- antibacterial agents
 - mortality rate comparisons *I*: 442
 - antibiotics, prophylactically *I*: 442
 - antibiotics, systemic: use of *I*: 431
 - antiseptic control of bacterial population *I*: 431-433
 - bacterial ecology *I*: 429-430, 433, 438, 458
 - β -haemolytic streptococcus *I*: 429-433
 - coagulation, disseminated intravascular *I*: 233-234
 - healing time: effect on *I*: 439
 - mafénide *I*: 458
 - mortality rate: effect on *I*: 437, 438
 - pulmonary complications *I*: 439, 441
 - compared with conventional therapy *I*: 445-446
 - management of *I*: 429-433
 - morbidity *I*: 429
 - mortality rate *I*: 429, 435, 442
 - normal body defence mechanisms *I*: 431
 - Pseudomonas* spp. *I*: 429-433
 - silver nitrate *I*: 432, 440-442, 447-449, 458
 - skin grafting *I*: 429, 447
 - sulphonamides *I*: 429, 432
 - see also burn wound sepsis
- Butyrophenone derivatives**
- Parkinsonism, drug-induced 2: 310-311
- BW 56072**
- see trimethoprim

C **C_{H_2O}**

- and urinary dilution *I*: 61

 C_{osm}

- and urinary dilution *I*: 61

CA-7

- see proteases

Caeruloplasmin

- contraceptives, oral 2: 148

Caffeine

- enzyme induction 2: 181

- Calcitonin**
 calcium balance in body 2: 62-63
 clinical appraisal 2: 62-63
 osteoporosis 2: 62-63
 Paget's disease 2: 63
 source 2: 62
 therapeutic role 2: 62-63
- Calcium**
 blood coagulation mechanism: role in 1: 231
- Calcium aspirin**
 see aspirin
- Calcium balance**
 calcitonin influence 2: 62-63
- Calcium excretion**
 ethacrynic acid 1: 72, 160
 frusemide 1: 74, 160
 mannitol 1: 160
 thiazides 1: 71, 160
- Calcium ions**
 digitalis: myocardium sensitised to 1: 83
 myoplasmic: digitalis action 1: 84
 vitamin B₁₂ absorption 2: 199-200
- Calcium metabolism**
 diuretics 1: 160
- Calcium receptor sites**
 diazoxide effect on 2: 74, 107
- Cancer**
 bleomycin 1: 487-488
 chemotherapy 1: 487-488
 contraceptives, hormonal 2: 152-156
- Cancer, breast**
 mortality rate 2: 28
- Cancer, oestrogens and 1: 411-412**
- Cancer mortality**
 compared with
 contraceptives, hormonal mortality rate 2: 25
- Cancer, uterus**
 mortality rate 2: 28
- Candidiasis**
 contraceptives, oral 1: 247
- Cannabis**
 see marihuana
- Capacitation, sperm**
 contraceptives, hormonal 1: 411
- Capreomycin**
 adverse reactions 1: 366
 antituberculosis activity 1: 350
 dosage
 tuberculosis: pulmonary 1: 366-367, 369
 nephrotoxicity 1: 366
 ocular reactions 1: opp 172
 renal damage 1: 366
 tuberculosis 1: 349-350
 tuberculosis: pulmonary
 combined with rifampicin + ethambutol 1:
 361-362, 366, 369-370
 resistance 1: 360-361, 366
- Carbachol**
 ocular reactions 1: opp 172
- Carbenicillin**
 pseudomonas infection, bronchial 1: 335-336
 synergy with gentamicin 1: 335-336
 synergy with trimethoprim 1: 36
- Carbenoxolone sodium**
 duodenal ulcer: placebo-controlled trials 1:
 94, 95
- Carbimazole**
 ocular reactions 1: opp 172
- Carbohydrate metabolism**
 chlormadinone 2: 144-145
 contraceptives, hormonal 1: 415-416
 contraceptives, oral 2: 144-146, 158-159
 contraceptives, oral: combined 2: 144
 contraceptives, oral + rheumatics 2: 144
 contraceptives, oral: sequential 2: 144
 diazoxide 2: 87
 ethinyloestradiol 2: 144
 hypoglycaemic agents, oral
 glibenclamide 1: 116-140
 impaired
 diazoxide 1: 159
 diuretics 1: 159
 ethacrynic acid 1: 160
 frusemide 1: 160
 thiazides 1: 159
 levodopa 2: 350, 378-380, 384
 mestranol 2: 144
 19-nortestosterones 2: 144
 rheumatics + contraceptives oral 2: 144
 see also glucose tolerance
- Carbon tetrachloride**
 metabolism 2: 180
- Carbonic anhydrase**
 acid-base balance: renal regulation 1: 62, 64
- Carbonic anhydrase inhibitors 1: 68-69**
 acidosis, metabolic 1: 69
 adverse reactions 1: 161
 hypersensitivity reactions 1: 161
 diuresis: mode of action 1: 68
 diuretic effect 1: 68
 hypokalaemia 1: 69, 158-159
 mafenide 1: 453, 457
 ocular reactions 1: opp 172
 renal mechanisms concerned with acid-base balance 1:
 63
 sodium reabsorption, nephron: site of inhibition 1: 77
 structural formula 1: 68
 p-sulphamoylbenzoic acid 1: 453, 456
- Carcinogenesis**
 enzyme induction 2: 229
- Carcinoma**
 bowel, surgery: large
 antibiotics: effect on incidence local recurrence 1:
 254
 contraceptives, oral: incidence shown by cervical
 smear 2: 153
- Carcinoma, prostate**
 diethylstilboestrol and cardiovascular disease and
 death incidence 2: 474
- Carcinoma, uterine cervical**
 contraception methods: incidence of 2: 153
- Cardiac asthma**
 see asthma, cardiac
- Cardiac failure 1: 142-147**
 diuretics: treatment of 1: 142

- Cardiac glycosides
 assay of *I*: 85
 dosage: determinants of *I*: 82-83
 ocular reactions *I*: opp 172
 use: current concepts *I*: 84-85
 see also digitalis, digoxin
- Cardiac index
 diazoxide 2: 89
- Cardiac oedema
 see oedema, cardiac
- Cardiac output
 contraceptives, oral causing increase 2: 143
 diazoxide 2: 88, 94, 116-118
 animals 2: 104-105
 diazoxide mechanism of response 2: 104-105
- Cardiac valves, prosthetic
 anticoagulant therapy: following insertion of *I*: 304
- Cardiogenic shock
 glucagon *I*: 326-327
- Cardiomyopathies
 digoxin dosage *I*: 83
- Cardiovascular disease
 associated with hypertension
 diazoxide 2: 84-85, 86-97
 diabetes: sulphonylureas and *I*: 112-114
- Cardiovascular disease incidence
 diethylstilboestrol for prostatic carcinoma 2: 474
- Cardiovascular haemodynamics
 diazoxide 2: 98, 115-118
 animals 2: 103-106
 diazoxide + frusemide 2: 98
 frusemide 2: 89
- Cardioversion
 quinidine prophylaxis after *I*: 337
- Catapres
 see clonidine
- Cataracts, posterior subcapsular
 corticosteroids *I*: 171
- Catarrh, vernal
 medrysone
 compared with placebo 2: 10
- Catechol-*O*-methyl transferase
 isoprenaline: substrate for *I*: 270, 294
 levodopa metabolism 2: 355
 salbutamol: not substrate for *I*: 270, 294
- Catecholamine
 amantadine causes enhanced release 2: 336
 biosynthesis 2: 332-333
 distribution 2: 327
- Catecholamine levels, brain
 levodopa effect 2: 331-332
 MK 485 2: 333-334
 Ro4-4602 2: 333-334
- Catecholamine release
 diazoxide 2: 109
- Catholic pill'
 see post-ovulatory pill
- Central nervous system, sickling
 contraceptives, hormonal 2: 41
- Central nervous system, trauma
 anticoagulant therapy *I*: 317
- Cephaloridine
 gonorrhoea *I*: 321
- Cephalothin
 gonorrhoea *I*: 320
- Cerebral artery occlusion
 contraceptives, hormonal 2: 32
- Cerebral embolism
 see thrombosis, cerebral
- Cerebral ischaemia
 see ischaemia, cerebral
- Cerebral ischaemic attack, transient
 anticoagulant therapy *I*: 306
- Cerebral thrombosis
 see thrombosis, cerebral
- Cerebri, pseudo-tumour
 contraceptives, hormonal 2: 32-33
- Cerebrospinal fluid
 diazoxide penetration 2: 134
 homovanillic acid 2: 354, 356
 levodopa 2: 353-354
 Parkinsonism
 homovanillic acid 2: 325
 5-hydroxyindoleacetic acid 2: 333-334
- Cerebrovascular accident
 anticoagulant therapy *I*: 316
 contraceptives, hormonal 2: 31-33, 157
- Cervical carcinoma
 intermenstrual bleeding *I*: 475
 postcoital bleeding *I*: 475
- Cervical epithelium
 contraceptives, hormonal 2: 152-153
- Cervical mucus
 composition *I*: 410
 menstrual cycle *I*: 401-402
- Cervical smear
 carcinoma incidence
 contraceptives, oral 2: 153
- Cervix
 chlormadinone acetate *I*: 411
 contraceptives, hormonal *I*: 410-411
 contraceptives, hormonal causing visible changes *I*: 415
 oestrogen-progestagen *I*: 411-412
 oestrogens *I*: 411-412
 progestagens *I*: 411-412
- Cervix uteri
 neoplasia
 contraceptives, hormonal 2: 152-153
- Chemoprophylaxis
 isoniazid 2: 236
- Chemotherapy
 cancer *I*: 487-488
 leukaemia *I*: 485-486, 487
- Childbirth
 mortality rate 2: 28
- Childhood
 nephrotic syndrome, steroid-sensitive relapsing
 cyclophosphamide 2: 60-61
- Children
 digoxin dosage *I*: 83
 pyoderma, treatment of 2: 58-59
- Chloasma
 see melasma
- Chloasma contraceptiveum
 see melasma

- Chloral hydrate**
 metabolism 2: 223
 ocular reactions 1: opp 172
 potentiation of warfarin-induced hypoprothrombin-
 emia 2: 54
- Chlorambucil**
 spermatogenesis, effect on 2: 60
- Chloramphenicol**
 antibacterial activity compared with
 trimethoprim-sulphamethoxazole 1: 37
 bioavailability 2: 449–450
 cholera El Tor
 compared with tetracycline and
 trimethoprim-sulphamethoxazole 1: 50
 elimination of bactericidal action of trimethoprim 1:
 36
 enteric fever
 compared with trimethoprim-sulphamethoxazole
 1: 15, 25, 27
 interaction with sulphonylureas 1: 136
 metabolism 2: 179, 232
 Parkinsonism: modifies symptoms 1: 88; 2: 326
 polymorphs 2: 449–450
- Chloramphenicol palmitate**
 bioavailability 2: 449
- Chloramphenicol stearate**
 bioavailability 2: 449
- Chlordiazepoxide**
 adverse reactions 1: 200, 204, 205, 208, 209
 anxiety neurosis
 compared with
 doxepin 1: 191, 200, 202, 204–205, 207–209
 dosage, anxiety neurosis 1: 200–202, 204–205,
 207–209
 hyperthyroid mice 1: 225
- Chlormadinone acetate**
 biological effect 1: 406
 blood clotting factors 1: 478
 blood clotting mechanism: effect on 2: 40
 carbohydrate metabolism 2: 144–145
 cervix: effect on 1: 411
 contraceptive failure rate 1: 467
 luteinising hormone peaks 1: 476
 mammary carcinoma in dogs 1: 471
 'mini pill' 1: 471
 neoplasm induction 1: 471
 ovulation induction 1: 476
 structural formula 1: 403
 tumours, fibroadenomatous 2: 154
- Chloroform**
 metabolism 2: 180
- 7-Chloro-3-methyl-1,2,4-benzothiadiazine-1,1-dioxide**
 see diazoxide
- Chloroquine**
 antirheumatic activity 2: 412
 malaria, falciparum: acute attacks
 compared with trimethoprim-sulfametopyrazine
 and pyrimethamine-sulfametopyrazine 1: 29
 ocular reactions 1: opp 172, 339
 porphyria cutanea tarda 1: 174
 rheumatoid arthritis 1: 339
 dosage 1: 339
 mode of action 1: 339
- Chlorothiazide**
 dosage: diuretic 1: 143
 heart failure: right-sided 1: 142
 hypertension 2: 74
 + clonidine 1: 249
 oedema, cardiac 1: 142–143, 146
 oedema, cirrhotic 1: 148
 proximal renal tubules: action on 1: 70
 structural formula 1: 69
- Chlorpromazine**
 adverse reactions 2: 473
 CNS depressant and tranquillising activity
 animals
 compared with
 doxepin 1: 217
 hyperthyroid mice 1: 225
 metabolism 2: 223
 ocular change occurring with long-term high dose
 therapy 2: 473
 Parkinsonism, drug-induced 2: 311
 pigmentation, ocular 1: 170
- Chlorpropamide**
 adverse reactions 1: 494–495
 antidiuretic action 1: 494–495
 compared with
 glibenclamide 1: 120, 121–122
 diabetes insipidus
 children 1: 494–495
 mode of action 1: 494
 mode of action
 diabetes insipidus 1: 494
 ocular reactions 1: opp 172
- Chlortetracycline**
 antibacterial activity compared with trimethoprim-
 sulphamethoxazole 1: 37
- Chlorthalidone**
 antihypertensive effect 1: 155
 chemical structure 1: 69
 combined with
 diazoxide 2: 95
 dosage, diuretic 1: 143
 duration of action 1: 69
 heart failure: right-sided 1: 143
 proximal renal tubules: action on 1: 70
- Cholera El Tor**
 trimethoprim-sulphamethoxazole
 compared with
 chloramphenicol and tetracycline 1: 50
- Cholestasis**
 contraceptives, hormonal 2: 159
 contraceptives, oral 2: 148–150
- Cholestasis, intrahepatic**
 phenobarbitone therapy 2: 183
- Cholesterol**
 contraceptives, oral 2: 146–147
- Cholinergic drugs**
 ocular reactions 1: opp 172
- Cholinergic hypersensitivity**
 levodopa 2: 344
- Cholinergic receptors**
 autonomic nervous system 1: 269
- Chorea**
 contraceptives, hormonal 2: 33

- Chorionic gonadotrophin
corpus luteum maintenance *I*: 401
- Chromosomal aberrations
contraceptives, hormonal *2*: 156
- Chromosomes
contraceptives, hormonal *1*: 413
norethynodrel *1*: 413
- Chrysarobin
ocular reactions *1*: opp 172
- CIBA 41, 166 Ba
see rifampicin
- C'I esterase inhibitor
fibrinolytic enzyme system: inhibitor of *1*: 231
- Circulation defects
mortality rate *2*: 28
- Cirrhosis, biliary
contraceptives, hormonal *2*: 159
- Cirrhosis, hepatic
see cirrhosis, liver
- Cirrhosis, liver
aldosterone antagonists *1*: 75
coagulation, disseminated intravascular *1*: 233–234
contraceptives, hormonal *1*: 415; *2*: 159
diuretics *1*: 147–149
management of ascites in patients with *2*: 241
spironolactone *1*: 75
- Cirrhosis, portal
contraceptives, hormonal *2*: 159
- Cirrhotic oedema
see oedema, cirrhotic
- Citric acid cycle
diazoxide effect on *2*: 111
- Cleft lip
anticonvulsant drugs in pregnancy: due to *1*: 92
- Cleft palate
anticonvulsant drugs in pregnancy: due to *1*: 92
phenytoin in pregnant rats: due to *1*: 92
trimethoprim-sulphamethoxazole in pregnant rats: due to *1*: 42
- Clioquinol
iodine metabolism *1*: 491
protein-bound-iodine *1*: 491
- Clofibrate
interaction with coumarin anticoagulants *1*: 313
- Clomiphene
amenorrhoea due to hormonal contraceptives *1*: 414
- Clonidine
adverse reactions *1*: 249
dosage *1*: 249
hypertension: in management of *1*: 248–249
+ chlorothiazide *1*: 249
+ methyl dopa *1*: 249
- Clopamide
dosage, diuretic *1*: 143
- Clorexolone
dosage, diuretic *1*: 143
heart failure: right-sided *1*: 143
- Clostridial infection
mafenide *1*: 450, 458
- Clot, blood
see blood clot
- Clotting, blood
see blood clotting
- Clotting factors
contraceptives, hormonal *2*: 39–40, 160
- Coagulation, blood
see blood coagulation mechanism
- Coagulation, disseminated intravascular
causes *1*: 310
coagulation factors: replacement of *1*: 311
disposal of deposited fibrin *1*: 311
heparin therapy *1*: 311
underlying disease: treatment of *1*: 311
clinical conditions associated with *1*: 234
management of *1*: 310–312
mechanism of *1*: 233
obstetric practice *1*: 372
pathogenesis *1*: 233
pathophysiology *1*: 233
- Cocaine
nasal mucosa response to *2*: 46–47
- Coeliac disease, adult
corticosteroids *1*: 175
- Coitus interruptus
contraceptive failure rate *1*: 467
- Colchicine
dosage *2*: 54
mode of action *2*: 54–55
plasma levels—implications as to pharmacology *2*: 54–55
- Colistin
burn wound sepsis *1*: 451
Klebsiella aerogenes infection *2*: 458
pseudomonas infection, bronchial *1*: 335–336
renal failure: drug intoxication
neurological episodes *1*: 169–170
- Collecting ducts
renal physiology *1*: 58
- Colon
motor activity effect of anaesthetised subjects:
atropine on *1*: 168
neostigmine on *1*: 168
- Compound 347
see ethrane
- Conception control
contraceptives, hormonal *1*: 462–465
intrauterine device *1*: 465
motivations required *1*: 463–464
- Condoms
contraceptive failure rate *1*: 467
- Congenital abnormalities
see dysmorphic drugs
- Conjugation
drug metabolism *2*: 179–180, 223
- Conjunctivitis
management *2*: 1
medrysone *2*: 3
- Conjunctivitis, allergic
medrysone *2*: 8–9
compared with
hydrocortisone *2*: 7
placebo *2*: 10
- Conjunctivitis, nonspecific
medrysone *2*: 8–9
- Conjunctivitis, vernal
medrysone *2*: 9
compared with dexamethasone *2*: 9

- Conovid
composition 1: 472
see also contraceptives, hormonal
- Conovid-E
composition 1: 473
- Contact lenses
contraceptives, hormonal causing discomfort in wearing 2: 34
- Contraception
uterine cervical carcinoma incidence 2: 153
- Contraceptives
failure rate 1: 467
pregnancy rates 1: 467
- Contraceptives, hormonal
abortions, spontaneous 2: 156
compared with
 intrauterine contraceptive device 2: 156
acceptability 1: 464-465
 cultural restrictions 1: 464-465
 to doctor 1: 464-465
 to government 1: 464-465
 to use 1: 465-466
adrenal function: effect on 1: 416-417
adverse reactions 1: 469, 471-474, 477; 2: 20-42, 138-156
amenorrhoea 1: 413-414
anaemia 2: 41-42
availability 1: 464, 469-471
availability in Australia and New Zealand 1: 472-473
biochemical effects 1: 415-417
biological effects 1: 402-406
 factors influencing 1: 40
 chlormadinone 1: 406
 ethinyloestradiol 1: 406
 weight gain 1: 406
blood clotting: effect on 2: 29, 39-40
blood clotting mechanism 2: 38-40
blood coagulation 2: 38-40
breast fibroadenomas 2: 154
breasts: effect on 1: 411-412
carbohydrate metabolism 1: 415-416; 2: 158-159
carcinogenesis 2: 154-156
central nervous system, sickling 2: 41
cerebral arterial thrombosis 2: 37-38
cerebral artery occlusion 2: 32
cerebral ischaemia 2: 157
cerebral thrombosis 2: 24, 25, 26, 27, 35, 36
cerebral venous thrombosis 2: 32
cerebrovascular disease 2: 31-33, 157
cervical epithelium 2: 152-153
chemistry 1: 402-404
cholestatic hepatobiliary illness 2: 159
choice of 1: 477-480
 oestrogen recommendation 1: 477
 progestagen recommendation 1: 477
 Scowen Committee recommendations 1: 477
 UK Family Planning Association recommendations 1: 477
choice of in patients with 1: 477-480
 atrophy, genital 1: 478
 breasts, lack of development 1: 478
 diabetes mellitus 1: 478
 dysmenorrhoea 1: 478
 endometriosis 1: 478
 hypercholesterolaemia 1: 478
 hypertension 1: 478
 lactating women 1: 479
 mastodynia 1: 478-479
 menopause 1: 479
 menorrhagia 1: 478
 migraine, cyclical 1: 479
 newly weds 1: 479
 ovulation pain 1: 478
 pelvic pain, intractable 1: 479
 premenstrual tension 1: 478
 thrombo-embolism 1: 478
 under-weight 1: 478
 chorea 2: 33
 chromosomal aberrations 2: 156
 cirrhosis, biliary 2: 159
 cirrhosis, liver 1: 415; 2: 159
 cirrhosis, portal 2: 159
 clotting factor concentration influenced by 2: 39-40
 combination regimen 1: 402
 adverse reactions 1: 471, 474-476
 amenorrhoea 1: 474
 breakthrough bleeding 1: 475
 cervix, visible changes in 1: 475
 endometrium: effect on 1: 409-410
 melasma 1: 475
 menstrual flow: alteration in duration and quality 1: 474
 migrainous headache 1: 474, 475
 psychiatric symptoms 1: 476
 weight gain 1: 474
 compared with
 mortality risk of automobile accidents 2: 25
 mortality risk of cancer 2: 25
 mortality risk of non users 2: 25
 mortality risk of pregnancy, delivery, puerperium 2: 25
 composition 1: 402-404
 conception control 1: 462-464
 contact lenses wearing, discomfort 2: 34
 continuous: progestagen only 1: 467, 471
 endometrium: effect on 1: 410
 contra-indications 2: 156-160
 coronary occlusion 2: 35
 coronary thrombosis 2: 24, 25, 26, 35
 corpus luteum: effect on 1: 408-409
 cryofibrinogenaemia 2: 41, 147, 157
 deep vein thrombosis 2: 25
 depression 2: 160
 diabetes mellitus 2: 158-159
 drug interactions 1: 405
 drug trials 1: 468-469
 duration of use 1: 465-466
 thrombo-embolism risk 2: 25
 dysplasia 2: 153
 efficacy 1: 466-467
 combination regimens 1: 466-467
 injectables 1: 467
 progestagens, low-dosage 1: 467
 sequential regimens 1: 466-467
 embryonic development 2: 156
 endometrial histology 2: 154

- eye, effect on 2: 33–34
 factor VII, effect on 2: 40
 factor X, effect on 2: 40
 fertility, subsequent: effects on 1: 413–414
 fertility control 1: 462–464
 fetus: effect on 1: 413
 fibrinolysis, effect on 2: 39
 fibroadenoma incidence
 compared with pre-oral contraceptives era 2: 156
 folate absorption, effect on 2: 41–42
 folate deficiency 2: 41–42
 glomerulonephritis 2: 157
 haematological studies 2: 41–42
 haemoglobinopathy, sickling 2: 41
 headache, temporal 2: 34
 heart disease 2: 157
 hepatitis, viral 1: 415; 2: 159
 hyperbilirubinemia 2: 159
 hypertension 2: 158
 toxaemia 2: 158
 intravascular thrombosis 2: 26
 ischaemia 2: 35–36
 plus other risks 2: 35
 jaundice 1: 415
 laboratory test modifications 2: 160
 clotting factors 2: 160
 liver function 2: 160
 metyrapone test 2: 160
 pregnanediol determination 2: 160
 thyroid function 2: 160
 laboratory values
 prothrombin time 2: 39
 lactation: effect on 1: 411–412
 laparotomy 2: 36
 lesions, vascular 2: 31–34
 liver dysfunction 2: 159
 α_2 -macroglobulin increase 2: 41, 157
 management of patient 2: 156–160
 neoplasia 2: 159
 menopause: effect on 1: 414
 menstrual cycle: effect on 1: 406–412
 mesenteric artery thrombosis 2: 36
 metabolic effects 1: 415–517
 metabolites in breast milk 1: 412
 migraine 2: 32, 157
 mode of action 1: 406–411
 cervix: effect on 1: 410–411
 endometrium: effects on 1: 409–410
 fallopian tubes: effect on 1: 408–409
 follicle stimulating hormone: effect on 1:
 407–408
 hypothalamic pituitary function: effect on 1:
 407–408
 luteinising hormone: effect on 1: 407
 ovaries: effect on 1: 408
 sperm capacitation 1: 411
 tubal factors 1: 408–409
 myocardial infarction 2: 24, 35
 neoplasia 2: 152–156
 breast tissue 2: 154–156
 cervix uteri 2: 152–153
 corpus uteri 2: 154
 neuritis, optic 2: 34
 neurological lesions 2: 31–33
 new methods 1: 480–482
 combination regimen, once-a-month 1:
 481
 postcoital pill 1: 481
 post-conception pill 1: 482
 post-ovulatory pill 1: 481
 progesteragen, sustained-release low-dose 1:
 480
 sequential regimen, reverse 1: 480
 ocular lesions 2: 33–34, 158
 oestrogen content
 thrombo-embolic incidence 2: 29–31
 oestrogen dominance desirable 1: 418
 atrophy, genital 1: 478
 oestrogen-progesteragen
 thrombo-embolism 2: 31
 ophthalmic manifestations 2: 33–34
 physiology 1: 402–404
 plasminogen, effect on 2: 39
 platelets, effect on 2: 39–40
 polyneuropathy 2: 34
 postcoital regimens 1: 402
 precautions in use 2: 156–160
 pregnancy cholestasis 2: 159
 progesteragen content
 thrombo-embolic incidence 2: 30–31
 progesteragen dominance desirable 1: 478
 menorrhagia 1: 478
 progesteragens, continuous administration 1: 402, 410,
 467, 471
 adverse reactions 1: 476–477
 progesteragens, injectable
 adverse reactions 1: 477
 protein-bound-iodine 2: 160
 puerperium: effect on 1: 412
 pulmonary embolism 2: 22, 23, 24, 25, 26, 27, 28, 29,
 35, 36,
 pseudo-tumour, cerebri incidence 2: 32–33
 'rebound' effect 1: 414
 renal diseases 2: 157
 retinal ischaemia 2: 157
 retinal oedema 2: 34
 safety, long-term 1: 465
 sequential regimens 1: 402
 adverse reactions 1: 476; 2: 23
 amenorrhoea 1: 476
 anti-oestrogenic effects 1: 480
 breakthrough bleeding 1: 480
 breast lesions 2: 154–156
 endometrium: effect on 1: 410
 leucorrhoea 1: 476
 menstrual flow 1: 476
 migrainous headache 1: 476
 thrombophlebitis incidence 2: 23
 serum alkaline phosphatase 2: 160
 sickle-cell haemoglobinopathy 2: 157
 sites of action in female 2: 401
 sperm capacitation 2: 411
 sperm transport 1: 410
 steroidal content 2: 29–31
 stroke incidence 2: 32
 stroke: vertebralbasilar area 2: 32

- surgery 2: 29, 157
 thrombi pathology: compared with controls 2: 37
 thrombo-embolism: 1: 412, 298; 2: 22-36, 157
 blood groups 2: 40-41
 epidemiological considerations 2: 22-31
 mortality risk 2: 24-25
 thrombo-embolism, postoperative 2: 29
 thrombo-embolism, previous history of 2: 31
 thrombo-embolism risk
 compared with non users 2: 26
 thrombophlebitis 2: 26, 36
 thrombophlebitis, incidence rate 2: 22-23
 thyroid function: effect on 1: 416
 transaminases, serum 2: 160
 tumours 2: 152
 uterine fibroids 2: 160
 vascular lesions, pathology associated with 2: 36-38
 vascular thrombosis 2: 35-36
 usage in Australia 1: 463, 466
 usage in New Zealand 1: 463, 466
 veins: effect on 2: 38
 venous thrombosis 2: 27, 29, 35, 36
 vision decrease 2: 34
 weight gain 2: 159
 see also contraceptives, injectable
 contraceptives, oral
 oestrogens
 progestagens
 Contraceptives, injectable
 advantages 1: 479
 adverse reactions 1: 477
 availability 1: 471
 in Australia and New Zealand 1: 473
 efficacy 1: 467
 medroxyprogesterone acetate 1: 467
 pregnancy rate 1: 467
 use-effectiveness 1: 467
 see also contraceptives, hormonal
 Contraceptives, oral
 adrenal function 2: 140
 adverse reactions 1: 247, 471, 474-476; 2: 138-156
 compared with intrauterine device 1: 479
 cutaneous 1: 247
 alopecia 2: 150-151
 angiomas, spider 2: 151
 angio-oedema 2: 151
 α -antitrypsin 2: 148
 availability 1: 469-471
 in Australia and New Zealand 1: 472-473
 blood pressure elevation 2: 139-144
 buccal mucosa 2: 151-152
 caeruloplasmin 2: 148
 carbohydrate metabolism 2: 144-146
 rheumatic patients 2: 144
 carcinoma: incidence shown by cervical smear 2: 153
 cardiac output increase 2: 143
 cholestasis of pregnancy 2: 148-150
 cholesterol levels 2: 146-147
 combination regimens 1: 466-467
 combined, once-a-month
 use-effectiveness 1: 481
 compared with
 intrauterine contraceptive device 2: 140-141
 cortisol plasma 2: 145
 cryofibrinogen 1: 147
 duration of use 1: 465-466
 erythema nodosum 2: 151
 failure rate 1: 467
 folate deficiency 2: 466-467
 gingivitis, hyperplastic 2: 151-152
 β_1 A-globulin 2: 148
 glucose plasma levels 2: 144-146
 growth hormone plasma level 2: 145
 + guanethidine 2: 140
 headache 2: 159
 herpes gestationis 2: 151
 hormones, plasma levels 2: 145
 hypertension 1: 96; 2: 139-144
 compared with
 cervical diaphragm 2: 141
 controlled by spironolactone 2: 143
 and guanethidine 1: 96
 haemodynamic changes 2: 143
 mechanism 2: 142-143
 hypertension, malignant 2: 140
 insulin plasma levels 2: 144-146
 iron protein binding 2: 195
 jaundice 2: 148-150
 lactate blood level 2: 144
 lactate dehydrogenase 2: 149
 lipid metabolism 2: 146-147
 liver dysfunction 2: 148-150, 159
 aetiological agent 2: 150
 pathogenesis 2: 148-150
 liver function studies 2: 149
 liver histology 2: 149-150
 lupus erythematosus, systemic 2: 151
 α_2 -macroglobulin 2: 147
 melasma 2: 150-151
 mestranol 2: 140
 metabolic processes: effect on 2: 144-148
 new methods 1: 480-482
 norethisterone 2: 140
 norethynodrel 2: 139
 ocular reactions 1: opp 172
 otolaryngological effects 2: 151
 phospholipids 2: 146
 photodermatitis 2: 151
 plasma volume increase 2: 143
 porphyria cutanea 2: 151
 pregnancy rates
 compared with other methods 1: 466-467
 progestagens, low-dose
 pregnancy rate 1: 467
 use-effectiveness 1: 467
 protein metabolism 2: 147-148
 pyruvate blood level 2: 144-146
 renal function 2: 140
 sequential regimens 1: 466-467
 carbohydrate metabolism 2: 144
 skin: effect on 2: 150-151
 spironolactone control of hypertension 2: 143
 stroke volume increase 2: 143
 thrombo-embolism 2: 22-36
 epidermiological considerations 2: 22-31
 thrombo-embolism, postoperative 1: 258

- thrombotic activity 2: 147
- thyroxine levels 2: 145
- transaminase levels 2: 149
- transferrin 2: 147-148
- triglycerides, plasma levels 2: 146-147
- use-effectiveness 1: 466-467
- vascular lesions in woman taking 1: 498
- weight gain 2: 139, 144
- see also contraceptives, hormonal
- Convulsions
 - levodopa 2: 386
- Coombs test, direct and indirect
 - levodopa 2: 379-380
- Copper metabolism, disorders of
 - see Wilson's disease
- Corneal healing
 - corticosteroids 1: 171
- Corneal heterograft reactions
 - medrysone effect on 2: 13-14
 - compared with
 - dexamethasone 2: 13-14
- Coronary artery disease
 - anticoagulant therapy 1: 305-306
 - diabetes: sulphonylureas and 1: 112
- Coronary insufficiency, acute
 - anticoagulant therapy 1: 305-306
- Coronary occlusion
 - see occlusion, coronary
- Coronary thrombosis
 - see thrombosis, coronary
- Corpus luteum
 - contraceptives, hormonal: effect on 1: 408-409
 - function in menstrual cycle 1: 401
- Corpus uteri
 - neoplasia
 - contraceptives, hormonal 2: 154
- Cortical diluting segment, nephron
 - urinary dilution 1: 61
- Corticosteroid responders
 - medrysone 2: 3, 11
- Corticosteroid secretion
 - levodopa 2: 351-352
- Corticosteroids
 - adverse reactions 1: 496
 - arthritis, rheumatoid 1: 495-496; 2: 411-412
 - coeliac disease, adult 1: 175
 - cortisone 1: 495-496
 - drug interactions
 - dexamethasone metabolism increased by phenytoin 1: 328
 - hyponatraemia: chronic dilutional 1: 157
 - indications in rheumatoid arthritis 1: 496
 - intermittent regimen
 - adrenocortical function 2: 235
 - intraocular pressure rise induction 2: 1-2, 10-12
 - long-term
 - adrenocortical function 2: 235
 - adverse reactions 2: 1
 - hypothalamo-pituitary adrenal function in
 - asthmatic patients 2: 234-235
 - intraocular pressure 2: 1
 - ocular reactions 1: opp 172
 - prednisone 1: 496
 - primary angle-closure glaucoma 2: 237
 - rheumatic disease 1: 495-496; 2: 411-412
- Corticosteroids, systemic
 - ocular reactions 1: 171-172
 - cataracts, subcapsular posterior 1: 171
 - exophthalmos 1: 171
 - intraocular pressure, increase 1: 171
 - myopia 1: 172
 - ocular palsy 1: 172
 - papilloedema 1: 172
 - retinopathy, hypertensive 1: 172
- Corticosteroids, topical
 - adverse reactions
 - cataracts, subcapsular posterior 1: 171
 - infection: increase in susceptibility 1: 171
 - intraocular pressure, increase 1: 171
 - contra-indications 2: 2
 - corneal healing 1: 171
 - diabetes mellitus 2: 2
 - glaucoma: management of 2: 2
 - herpes simplex 1: 171
 - intraocular pressure, genetic determination 2: 1-2
 - Krukenberg spindles 2: 2
 - myopia 2: 2
 - ocular reactions 1: 171-172
 - precautions 2: 18
- Corticotrophins
 - arthritis 2: 411-412
- Cortisol
 - see hydrocortisone
- Cortisol, plasma
 - contraceptives, hormonal 1: 417
 - contraceptives, oral 2: 145
 - method assessing premedicants 1: 340
- Cortisol secretion
 - diazoxide effect on 2: 123-124
- Coumarins
 - absorption 1: 237
 - adverse reactions 1: 315
 - antagonist of 1: 241
 - anticoagulant activity 1: 236
 - blood coagulation mechanism: effect on 1: 230
 - breast-milk 1: 308
 - clotting factors: influence on 1: 236
 - contra-indications 1: 316
 - dosage 1: 236
 - drug interactions 1: 313-314, 392; 2: 54, 131-132
 - drugs affecting response 1: 313-314
 - potentiation of other drugs 1: 314
 - duration of effect 1: 236
 - excretion 1: 237
 - fetal haemorrhage 1: 308
 - haematological reactions 1: 315
 - host determinants of response 1: 313
 - interaction with
 - chloral hydrate 2: 54
 - diazoxide 2: 131-132
 - rifampicin 1: 392
 - laboratory control 1: 243
 - metabolism 1: 237
 - mode of action 1: 236-237
 - non-haematological side-effects 1: 315
 - placental transfer 1: 308